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Abstract Tumor necrosis factor–α (TNF-α) blockers are a pop-
ular therapeutic choice in a number of inflammatory diseases.
Thus far, five TNF- α blockers have been approved for clinical
use (etanercept, infliximab, adalimumab, golimumab. and
certolizumab). Despite being considered relatively safe, serious
side effects associated with immune suppression have been re-
ported, including central and peripheral nervous system (CNS)
demyelinating disorders. It is still elusive whether these events
are mere coincidence or a side effect of anti-TNF-α use. In this
paper, we review the published case reports of CNS demyelin-
ation associated with anti-TNF-α therapy and present the follow-
up of our 4 previously reported patients who developed neuro-
logic symptoms suggestive of CNS demyelination after having
received anti-TNF-α treatment. We also discuss the possible role
of TNF-α blockers in demyelination.
Keywords Anti-TNF-α . Demyelination . Tumor necrosis
factor . Multiple sclerosis
Introduction
Tumor necrosis factor-α (TNF-α) blockers present a revolu-
tionizing therapeutic choice for a number of inflammatory
diseases such as Crohn’s disease (CD), ankylosing spondylitis
(AS), and rheumatoid arthritis (RA). Several terms such as
TNF-α blockers, anti-TNF-α agents, TNF-α antagonists,
and TNF-α inhibitors are used interchangeably, all describing
the same biological agents. Henceforth in our paper, we will
use the term TNF-α blocker for clarity.
These agents are more effective than traditional disease
modifying drugs (DMDs), controlling disease activity and
preventing underlying structural tissue damage. Although
they are relatively safe, an increasing number of neurologic
side effects have been reported in the literature, consisting of
central and peripheral nervous system demyelinating events.
These adverse events suggest a possible relationship between
anti-TNF-α use and demyelination [1]. However, it remains
uncertain whether these episodes are coincidental or causally
linked, or how TNF-α blockage may possibly trigger or ex-
acerbate demyelination.
In this paper, we review the pathogenic and protective
functions of TNF-α, the role of TNF-α blockers in CNS de-
myelination and the CNS demyelinating cases reported in the
literature to be related to anti-TNF-α therapy. We also present
the follow-up of our 4 previously reported patients [2] who
developed neurologic symptoms suggestive of CNS demye-
lination after having received TNF-α blockers.
TNF-αMechanism of Action
TNF-α is a pleiotropic cytokine, with a wide range of functions:
homeostatic, immune, and inflammatory. The beneficial homeo-
static functions of TNF-α include defense against pathogens,
development of lymphoid organ architecture, resolution of in-
flammation, tissue regeneration, immune regulation, and inhibi-
tion of tumor growth. The pathogenic functions of TNF-α com-
prise triggering of inflammation, stimulation of vascular
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endothelium, proliferation of immune cells, and tissue damage
[3, 4]. Under physiological conditions, macrophages, lympho-
cytes (T and B), natural killer cells, dendritic cells, and mono-
cytes produce TNF-α in the periphery [5], while in the CNS
TNF-α is produced mainly by migroglia, neurons, and astro-
cytes [4–7].
TNF-α is produced initially as a transmembrane molecule
(tmTNF). Subsequently, it is released from cells as a soluble
cytokine (sTNF) via regulated cleavage of tmTNF by TNF-α
converting enzyme (TACE). Both forms of TNF-α are biolog-
ically active and interact with two receptors (TNFR1 and
TNFR2) with different affinity. sTNF has a higher affinity for
TNFR1, contains a death domain, and mediates apoptosis and
chronic inflammation [8]. tmTNF has a higher affinity for
TNFR2, activating genes important for cell survival, resolution
of inflammation, and even myelination. TNFR1 is expressed in
all cell types, whereas TNFR2 is expressed mainly on neurons,
immune cells, and endothelial cells [9••, 10, 11].
At low levels in tissues, TNF-α exerts beneficial homeostatic
functions, as it enhances host defense mechanisms against intra-
cellular pathogens, particularly mycobacteria [12]. At elevated
concentrations, TNF-α can promote inflammation and organ in-
jury [13]. In disease states, TNF-α is considered to be a proin-
flammatory cytokine that is promptly produced in response to
stimuli, both systemically and locally in the affected tissues, pre-
dominantly by activated macrophages and monocytes [13].
Moreover, circulating TNF-α crosses the blood brain barrier
(BBB) into the brain [14]. Inflammatory stimuli in the CNS
induce TNF-α production mainly by microglia, neurons, and
infiltrating immune cells [9••].
Types and Mechanism of Action of TNF-α Blockers
Five anti-TNF-α blockers are approved for clinical use:
etanercept (circulating receptor fusion protein), infliximab,
adalimumab, and golimumab (IgG monoclonal antibodies),
and certolizumab (PEGylated Fab1 fragment of an IgG1
monoclonal antibody) [15]. Both receptor and antibody based
TNF-α blockers act as antagonists by blocking tmTNF inter-
actions with TNFR1/2, and as agonists, by inverting signal
leading to apoptosis, cell activation, or cytokine inhibition
[5, 16, 17]. Etanercept also binds to lymphotoxin LTα3,
which is structurally similar to sTNF, with equivalent or great-
er affinity than sTNF [16].
Compared with the traditional DMDs, TNF-α blockers are
more efficacious, with faster onset of action and more effec-
tive control of disease progression. These characteristics have
made them an appealing option in refractory cases [18, 19].
Clinical Uses of TNF-α Blockers
TNF-α blockers present a revolutionizing therapeutic choice
for inflammatory diseases such as RA, AS, plaque psoriasis,
psoriatic arthritis, juvenile polyarticular rheumatoid arthritis,
and inflammatory bowel disease (CD and ulcerative colitis).
TNF-α blockers are also used off-label for a number of other
inflammatory conditions such as sarcoidosis, hidradenitis
suppuritiva, Adamantiades-Behcet's disease, pyoderma
gangrenosum, dermatomyositis, scleroderma, noninfectious
uveitis, and others [20, 21]. Novel indications for the use of
TNF-α blockers are under investigation, and new TNF-α
blockers are being evaluated.
Anti-TNF-α Blockers’ Trials for Multiple Sclerosis
Initial studies in experimental autoimmune encephalomyelitis
(EAE) animal models of multiple sclerosis (MS) showed ben-
eficial effects of TNF-α blockers. Subsequently, given their
anti-inflammatory effects, clinical trials of infliximab [22] and
lenercept [23] (a receptor-based TNF-α blocker) were carried
out in people with MS with surprisingly unfavorable results.
Specifically, in an open label phase I trial with infliximab, 2
patients with rapidly progressive MS showed increased dis-
ease activity and MRI lesion load [22]. Furthermore, a ran-
domized double-blind placebo-controlled multicenter trial in
168 relapsing-remitting MS patients with lenercept was
stopped prematurely due to a dose-dependent increase in re-
lapse rate, attack duration, and severity of exacerbations [23].
These trials suggested that non-selective inhibition of
TNF-α is harmful in MS and that TNF-α exerts both potent
pro-inflammatory effects and essential protective functions in
the CNS under pathological conditions [9••].
Side Effects of TNF-α Blockers
The efficacy of TNF-α blockers in inflammatory conditions has
increased their use. Despite their relatively safe profile, well-
known adverse events include injection site reactions, risk of
infections (especially tuberculosis reactivation), congestive
heart failure, hemocytopenia, and T-cell lymphomas [24, 25].
Reports of autoimmune diseases, including lupus-like syn-
dromes and vasculitis [26], diabetes mellitus, psoriasis, intersti-
tial lung diseases, sarcoidosis, autoimmune hepatitis, uveitis,
antiphospholipid syndrome, myositis, and myasthenia gravis
have also been published [1, 27–29].
With the widespread use of TNF-α blockers, a growing
number of demyelinating events have been reported, includ-
ing CNS demyelinating disorders [MS, optic neuritis (ON),
acute transverse myelitis (TM)], as well as peripheral nervous
system disorders (Guillain-Barré syndrome,Miller Fisher syn-
drome, chronic inflammatory demyelinating polyneuropathy,
multifocal motor neuropathy with conduction block,
mononeuropathy multiplex, and axonal sensorimotor
polyneuropathies) [1, 30]. It still remains unclear whether
these events are coincidental or are actually side effects of
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anti-TNF-α use. Even more elusive remains the underlying
pathogenic mechanism [3].
TNF-α Effect on Demyelination
The pleiotropic functions of TNF-α often show contradictory
effects, particularly in the CNS. TNF-α and its receptors can
either promote neuroinflammation and secondary neuronal
damage, or exert protective functions under pathological con-
ditions. Furthermore, TNF-α exerts distinctive actions at dif-
ferent stages of autoimmune demyelination: sTNF, but not
tmTNF, promotes inflammation and disease onset, whereas
sTNF and/or tmTNF have protective functions in established
disease by reducing the extent and severity of autoimmune
inflammation. sTNF mediates the proinflammatory effects of
TNF-α via TNFR1 signaling. TNFR1 plays a critical role for
the onset of CNS autoimmune disease, through induction of a
pro-inflammatory environment in the CNS, but subsequently
suppresses local inflammation either indirectly, mediating
neuroprotection, or directly, promoting repair processes
[9••]. Elevated production of TNF-α was observed in patients
and animal models of MS. TNF-α overexpressing transgenic
mice develop spontaneous demyelination that reverses with
anti-TNF-α administration [9••], whereas demyelination is
delayed in TNF-α deficient mice [31]. TNF-α has been found
to increase permeability of the BBB [14] and high levels of
TNF-α were found in active central and peripheral demyelin-
ating lesions [32, 33] as well as in the serum, cerebrospinal
fluid (CSF), and brain plaques of MS patients [34] correlating
with disease severity or exacerbation [35, 36]. It was recently
shown that TNF-α is predominantly produced by both mac-
rophages and microglia during acute EAE and is decreased
during remission, whereas TNF-α is sustained by infiltrating
macrophages in progressive EAE, enhancing clinical disabil-
ity and CNS inflammation [37•]. TNF-α has also been impli-
cated in promoting macrophage polarization to a pro-
inflammatory M1 phenotype [38•]. Additionally, TNF-α
seems to exert a protective role in the periphery and a patho-
genic role in the CNS by suppressing encephalitogenic T cell
production of Th1 and Th17 in lymphoid organs, while pro-
moting immunocyte infiltration in the CNS through chemo-
kine production, exacerbating disease severity [39]. Inhibition
of both sTNF and tmTNF does not seem to protect against
demyelination [8].
Besides being crucial in host defense and inflammation and
accelerating acute demyelinating processes, TNF-α is also
necessary for triggering remyelination [8, 39] and promoting
the proliferation of oligodendrocyte precursor cells [40]. In
later stages of MS, TNF-α has shown immunosuppressive
properties. In early studies of animal models, inhibition of
TNF-α resulted in EAE improvement or protection against
demyelination [31, 41–43]. In recent studies, selective inhibi-
tion of sTNFwas found to be beneficial during EAE, implying
that the protective effects of TNF-α are exerted through the
interaction of tmTNF with TNFR2 [8]. Evidence from EAE
models suggest that remyelination in the CNS necessitates the
expression and activity of TNFR2 and CXCR4 by oligoden-
drocyte progenitor cells, promoting their proliferation and dif-
ferentiation into mature oligodendrocytes [40], and that selec-
tive inhibition of tmTNF/TNFR2 leads to demyelination and
oligodendrocyte apoptosis [44].
Interestingly, MS susceptibility has been associated with a
single nucleotide polymorphism (SNP) in a gene, encoding
TNF receptor 1 (TNFR1), the TNFRSF1A gene. This SNP in
TNFR1 leads to expression of a soluble form of TNFR1 that
inhibits TNF-α in humans and this may play a role in MS
development in some individuals, possibly mimicking the ef-
fects of TNF-α blockers [45].
Theories About the Mechanism of Action of Anti-TNF-α
Therapy in CNS Demyelination
Since TNF-α is implicated in demyelinating processes,
TNF-α blockers were considered as a potential therapeutic
choice inMS. However, the negative outcomes of these agents
in MS trials [22, 23] and the reports of demyelinating events
following their use for other disorders raised the suspicion that
use of these drugs could be a risk factor of demyelination. In
an attempt to clarify the potential biological role of TNF-α
blockers in triggering or aggravating demyelination, several
theories have been proposed [46]:
1. TNF-α blockers cannot penetrate the intact BBB to sup-
press demyelination but they can enhance demyelination
through increased ingress of peripheral autoreactive T-
cells into the CNS (lack of entry theory). This theory
provides a possible explanation for the failure of anti-
TNF-α blockers in reducing demyelination and for their
effect on aggravating MS [3, 47].
2. TNF-α blockers may aggravate CNS demyelination by
decreasing TNFR2 receptors, which are necessary for
the proliferation of immature oligodendrocytes and mye-
lin repair [48–54].
3. TNF-α blockers could alter cytokine responses by down-
regulating interleukin-10 and upregulating interleukin-12
and interferon-γ, creating a profile similar to that of MS
patients [54, 55•, 56].
4. TNF-α blockers may deactivate TNF-α systemically, but
not within the CNS (due to BBB impermeability), leading
to a high concentration of TNF-α in the CNS (“sponge
effect”) [3, 47].
5. There may be systematic dysregulation of TNF-α in pa-
tients with RRMS, as was shown in a recent study of
Mausner-Fainberg et al [57••], in which increased serum
neutralization capacity of TNF-α in RRMS patients was
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observed. These findings offer a possible explanation for
the demyelinating events after TNF-α blockade.
6. Finally, TNF-α blockers may unmask an underlying la-
tent infection, which can lead to autoimmune demyelin-
ation [5, 47, 58, 59].
Reviewed Cases
We present the follow-up of our 4 previously reported patients,
2 with RA and 2with ASwho developed neurologic symptoms
following anti-TNF-α exposure [2]. We also review the cases
of CNS demyelination associated with TNF-α blockers, pub-
lished in the medical literature between January 1990 and
August 2016. We conducted a PubMed literature search of
available material on documented CNS demyelination in pa-
tients receiving TNF-α blockers. Articles from PubMed were
obtained using the search terms “Demyelinating Disease,”
“Multiple Sclerosis,” “Optic neuritis,” and “Tumor Necrosis
Factor-α.” Including our 4 patients, 122 cases with CNS demy-
elinating events during anti-TNF-α treatment were identified:
69 case reports and 53 cases from the Spanish Registry of
biological therapies in rheumatic diseases and an adverse event
data base [30, 49, 50, 56, 60–90, 91•, 92••, 93].
All cases are summarized in Table 1; 75 patients were fe-
male (61%) and 47 were male (39%) with a mean age of
45.29 years (SD: 14.89). Only 3 patients were reported to have
a family history of MS; 61 patients (50%) had RA, 14 (11%)
had AS, 20 (16%) had PsA, 10 (8%) had CD, and 18 (15%)
had other rheumatologic and inflammatory diseases. Fifty
(41%) patients were treated with infliximab, 57 (47%) with
etanercept, 19 (16%) with adalimumab, and 1 (1%) with
golimumab. Three patients (2.5%) received more than one
TNF-α blocker successively. Seven patients (6%) were re-
ceiving combined therapy with TNF-α blockers and metho-
trexate (MTX) at the onset of symptoms; 28 patients (23%)
had received different DMDs before the initiation of anti-
TNF-α treatment, mostly MTX. The mean time of exposure
to TNF-α blockers, before the onset of symptoms, was
17.61 months (SD: 18.07, range: 3 d–6 y). According to pre-
vious studies, the interval between anti-TNF-α initiation and
onset of symptoms was approximately 5 months (1 wk–15
mo) [30]. At presentation, diagnosis of MS was confirmed
in 26 patients (21%), ON in 46 (38%), monophasic demyelin-
ating event (MDE) in 37 (30%), progressive multifocal
leukoencephalopathy (PML) in 3 (3%), tumefactive lesions
in 2 (2%), TM in 6 (5%), and leukoencephalopathy in 2
(2%); 39% of the cases were treated with pulse steroid therapy
(48 patients), whereas oral steroids were administered to 12%
of patients (15 patients). The mean follow-up time was
12.78 months (SD 12.71). Interestingly, 7 patients were diag-
nosed with MS after longer follow-up (mean follow up
20.43 months). TNF-α blockers were discontinued in all ex-
cept 2 patients, where available information is missing. In 1
patient treatment was restarted with a positive rechallenge
phenomenon. Complete recovery after the initial therapy
was reported in 44 patients (36%) and partial in 26 patients
(21%), whereas no resolution of symptoms was described in
34 patients (28%). Two patients with PML (1.6%) and 1 with
MDE (0.8%) died.
Our Experience
Our patients had been treated with TNF-α blockers previously
or were taking them at the onset of symptoms; thus, a corre-
lation between the treatment and demyelination was speculat-
ed. Anti-TNF-α treatment was discontinued as soon as demy-
elination was suspected and steroids were administered intra-
venously with consequent clinical improvement. During the
5-year follow-up, 2 patients remained stable without relapses
or new MRI lesions, whereas the other 2, both male, had
clinical relapses and radiological deterioration with new brain
and spinal cord (SC) demyelinating lesions. One of them re-
quired pulsed steroid treatment, whereas the other had a minor
relapse that subsided without therapy (Fig. 1). It is remarkable
that both these patients had a family history of autoimmune
diseases, a fact that could indicate an increased susceptibility
of CNS demyelination, irrespectively of anti-TNF-α treatment
[35] and should be taken into consideration during the clinical
evaluation of the patients. On the other hand, anti-TNF-α
agents could potentially aggravate demyelination in genetical-
ly predisposed patients (such as first degree relatives of MS
patients as in our second case). Therefore, the assumption that
in our cases treatment might have unmasked pre-existing la-
tent MS seems plausible. Nevertheless, such an association
could not be established, since neurologic examination or
brain MRI had not been performed prior to anti-TNF-α treat-
ment initiation.
None of our patients received specific MS treatment, al-
though all of them were treated with immunesuppressants
for their initial autoimmune disease (AS or PsA), after the
presenting demyelinating event.
Outcome ofRheumatic Disease After TNF-αBlocker
Discontinuation
TNF-α blockers are currently recommended for patients not
responding to at least 2 different DMDs and seem to have an
excellent and sustained therapeutic outcome: 80% of patients
improve rapidly and 50% have complete remission [94, 95].
Patients who receive TNF-α blockers, therefore, are refractory
to standard medical therapy. Unfortunately, most reports of
demyelinating events after administration of TNF-α blockers
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focus on the clinical evolution of demyelination and do not
provide information on the course of the underlying rheumatic
or inflammatory disease. Based on the data collected, it ap-
pears that the rheumatic/inflammatory disease follows an in-
dependent course and most patients continue treatment with
DMDs, often with poor results [71].
Outcome of CNS Demyelination Associated
with TNF-α Blockers
Although CNS demyelination after treatment with TNF-α
blockers is not necessarily associated with the duration of
the therapy and drug discontinuation does not always lead to
improvement [93], treatment should be discontinued at the
appearance of unexplained neurologic symptoms. On the oth-
er hand, there are no clear recommendations for the manage-
ment of the CNS demyelinating process. In most cases, the
therapeutic regimen is based on the standard guidelines for
CNS demyelination. Steroids are usually administered, either
pulses of methylprednisolone or oral glucocorticosteroids,
with good results in the short term, although the course of
the demyelinating disease appears unpredictable [1, 30].
Arguments for a Possible Relationship
Between Anti-TNF-α Therapy and Demyelination
Several Factors Suggest an Etiological Role of TNF-α
Blockers in CNS Demyelination
1. Reported cases and pathogenic theories
The large number of CNS and peripheral demyelinating
disorders after TNF-α blocker administration published in
the literature [2, 30, 49–54, 55•, 56, 57••, 58–90, 91•, 92••,
93] and the 2 clinical trials of TNF-α blockers in MS patients
showing an increase of demyelinating events [22, 23] raise the
question of a possible association. Moreover, many theories
support a possible correlation of non-selective TNF-α block-
ade with demyelination.
2. Miller criteria
Some of the published cases meet the Miller criteria [96],
attributing the CNS demyelinating events to the TNF-a blockade.
According toMiller criteria, the definition of drug-induced illness
comprises 8 elements and requires the presence of at least 4:
temporal association, improvement of symptoms after treatment
discontinuation, positive rechallenge phenomenon, and other
CNS demyelinating events reported in the literature [96]. In most
cases, a temporal relation to anti-TNF-α treatment is suggested
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[27, 97]. Few cases show a rechallenge phenomenon and even
fewer argue in favor of the onset of a demyelinating process
directly after anti-TNF-α exposure [67].
3. Age of onset
The peak age of MS onset is 20–40 years old, whereas the
mean age of RA onset is 40–60 years old. In our review, the
mean age of the patients who developed CNS demyelination
was 45.47 years. This delayed onset of demyelination could
suggest a possible association with anti-TNF-α use.
Arguments Against a Possible Relationship
Between TNF-α Blockers and Demyelination
Several factors, on the other hand, challenge a causal relation-
ship of anti-TNF-α treatment with the appearance of CNS
demyelination
1. Incidence
Although over 2 million patients with rheumatic and
other chronic inflammatory diseases have been treated
with anti-TNF-α therapies [98••], the overall number
of the published demyelinating events is relatively
small. In initial reports, the estimated risk of CNS de-
myelination after anti-TNF-α therapy ranged widely be-
tween 30% and that of the general population [30, 58,
69]. Interestingly, randomized controlled trials, develop-
mental and post-marketing programs, and retrospective
long-term safety studies revealed no increase of demye-
linating events compared with the actual incidence of
MS [27, 99, 100]. A Danish population-based cohort
study of IBD patients exposed to TNF-α blockers
showed a 2-fold increase in relative risk, but a low
absolute risk of CNS demyelination.
2. However, it should be emphasized that demyelinating events
could be silent and therefore under-reported, making it dif-
ficult to estimate the actual incidence of CNS demyelination
after anti-TNF-α therapy [75]. This issue was addressed in a
prospective study of patients with rheumatic diseases before
Fig. 1 (a) and (b): axial T2-weighted cervical spine MRI of the index
case 1, treated with ETN for 8 months for PsA, who was diagnosed with
MS on follow-up. (a) At initial presentation, a central posterior
demyelinating lesion on C3 level that showed gadolinium enhancement
on T1-sequences (not shown). (b) Four years after etanecept
discontinuation, disappearance of the lesion. (c)–(f) Brain and cervical
spine MRI of the index case 2, with AS and a family history of MS,
treated with adalimumab for 36 months, who was also diagnosed with
MS. (c) Brain flair and (d) cervical spine T2-weighted sagittal MRI at
symptom onset, and (e)–(f) 4 years after anti-TNF-a cessation. Note the
increase of cerebral demyelinating lesions, with marked atrophy, and the
disappearance of the lesion on C7 level
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receiving TNF-α blockers. Two out of 77 patients had MRI
lesions and 4 developed demyelination, but the overall rate
of neurologic adverse events was comparable with the group
of patients who had not received anti TNF -α blockers
[92••]. Autoimmunity
Patients with autoimmune diseases could be genetically prone
to develop another autoimmune disease [101], a fact that might
predispose them to CNS demyelination regardless of anti-TNF-α
use. On the other hand, the use of such therapies could merely
unmask latent MS [53]. Moreover, demyelination could be part
of an overlapping syndrome with other rheumatologic diseases.
Although RA patients showed no increase in latent demyelin-
ation [97], IBD patients appeared to have a high occurrence of
CNS T2 white matter lesions and a higher risk of developing
CNS demyelination [77, 102–105]. Despite the fact that several
case reports revealed a higher prevalence of RA, psoriasis, and
goiter in MS patients [52–54, 55•, 56, 57••, 58], no further accu-
mulation of autoimmune diseases was found in a multi-center
population-based study [106].
3. Previous treatments
TNF-α blockers are therapeutic options for patients who
have already received treatment with a number of other immu-
nosuppressive agents, most commonly methotrexate. Although
methotrexate is an immunosuppressant extensively used inMS,
it has been associated with demyelinating events at high doses
and in combination with cranial radiotherapy [107].
4. Rechallenge phenomenon
The rechallenge phenomenon could be simply explained by
the relapsing-remitting nature of MS [108]. On the other hand,
most of the patients who were retreated with TNF-α blockers
after a demyelinating event did not experience new neurologic
symptoms.
5. Time interval between therapy and symptom onset
The interval between treatment administration and symp-
tom initiation varies greatly, from 5 months up to 4 years [30].
In the presently reviewed cases, symptoms appeared after a
mean exposure time of 17.61 months. However, given that the
anti-TNF-α effect could last longer than its half-life, resulting
in delayed side effects [1], symptoms may even emerge after
treatment cessation [30].
6. Outcome
In most published cases, demyelination was either slowly
progressing or stopped after anti-TNF-α discontinuation. This
could suggest that anti-TNF-α therapy exerts a protective
effect in patients already suffering from latent MS, or has a
short lasting harmful impact.
Conclusions
Anti-TNF-α blockers have reshaped the treatment of rheumatoid
and autoimmune diseases, being the most effective drugs in our
therapeutic armentarium. However, TNF-α functioning, espe-
cially in the CNS, is still incompletely understood, setting restric-
tions on their unlimited use. To date, the reported cases of demy-
elination address the possibility of a causal association. Our pre-
vious study raised the question whether the demyelinating events
in patients who had previously received TNF-α blockers were
the result of uncovering latent MS, onset of a novel demyelinat-
ing event (MS or MS-like syndrome), or were merely an acci-
dental coexistence of the 2 disorders. Long-term follow-up of
these patients is required to properly diagnose, determine the
clinical course, and point out the potential differences from typ-
ical MS. Complete symptom remission after therapy withdrawal
or a positive rechallenge phenomenon could prove causality,
although the nature ofMS,with relapses and remissions of symp-
toms, argues against such a relationship. The complexity of the
biological functions of TNF-α further complicates the issue.
Although several theoretical explanations of demyelination after
TNF-α blockade have been proposed, the relation of these events
with the use of TNF-α blockers remains to be elucidated.
Nevertheless, according to the current guidelines, avoiding
the use of anti-TNF-α therapy is recommended in patients with
a history or familial occurrence of MS or other demyelinating
diseases. Furthermore, in case of appearance of neurologic symp-
toms, the patient should undergo a thorough neurologic assess-
ment (level of evidence III and a grade of recommendation B)
[108]. Besides thosewith a family history ofCNSdemyelination,
patients with familial occurrence of systemic autoimmune dis-
eases (as our first case) might also be at increased risk of CNS
demyelination with anti-TNF-α treatment. Although MRI imag-
ing of the brain before starting anti-TNF-α treatment is not rec-
ommended [108], it could be useful in revealing possible silent
demyelinating lesions [56], especially in patients with a family
history of MS or systemic autoimmune diseases.
We propose careful clinical evaluation of candidates for
TNF-α blockers, including neurologic assessment before drug
initiation and close neurologic monitoring, in order to diagnose
a possible demyelinating condition in as timely a manner as
possible, especially in high risk patients.
Future Prospects
Anti-TNF-α therapies undoubtedly are an excellent therapeu-
tic choice in refractory inflammatory diseases. On the other
hand, considering the possibility of demyelination, more
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specific TNF-α-targeting drugs might be safer. Anti-TNF-α
therapies that either target TNFR1 while sparing TNFR2 sig-
naling selectively, or inhibit sTNF (currently under investiga-
tion) could potentially minimize the adverse events in the
CNS. Furthermore, based on the observation that TNFR2 an-
tagonizes TNFR1 signaling, either TNFR2 agonists or in-
creased expression of TNFR2 by gene therapy might be ben-
eficial [108]. The possibility of a more susceptible patient
population that should be cautiously treated with TNF-α
blockers must be taken into account, and in these cases the
detection of a potential predictive marker could be helpful.
Whether TNF-α blockers directly cause demyelination (either
with a progressive or a monophasic course) or they trigger pre-
existing demyelinating predisposition, still remains controversial.
Unfortunately, only few patients with a satisfactory follow-up are
reported in the literature. Systematic and long-term follow-up of
affected patients might shed light to these still unanswered ques-
tions and help distinguish which patients will safely benefit from
anti-TNF-α treatment for their inflammatory disease.
Furthermore, elucidation of the exact mechanism of the appar-
ently paradoxical response to TNF-α blockers in MS might im-
prove our understanding of the pathophysiology of MS.
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